Get the Stockscreener App
5.37
15.17%
-0.96
After Hours:
5.40
0.03
+0.56%
Xenetic Biosciences Inc stock is traded at $5.37, with a volume of 362.91K.
It is down -15.17% in the last 24 hours and up +49.17% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
See More
Previous Close:
$6.33
Open:
$6.43
24h Volume:
362.91K
Relative Volume:
0.47
Market Cap:
$8.28M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.9527
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
+65.78%
1M Performance:
+49.17%
6M Performance:
+133.48%
1Y Performance:
+44.35%
1-Day Range:
$5.37
$6.515
1-Week Range:
$3.24
$13.93
52-Week Range:
$2.20
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
5.37 | 9.76M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Visual trend scoring systems applied to Xenetic Biosciences Inc.Portfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
What MACD and RSI say about Xenetic Biosciences Inc.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Fall River Herald News
Is Xenetic Biosciences Inc a good long term investmentEvening Star Patterns & Double Digit Portfolio Growth - earlytimes.in
Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Xenetic Biosciences prices $4.5 million common stock offering By Investing.com - Investing.com Nigeria
Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges - Benzinga
Can Xenetic Biosciences Inc. (3XB0) stock surprise with quarterly resultsEarnings Recap Report & Advanced Swing Trade Entry Alerts - newser.com
Xenetic Biosciences Prices $4.5 Million Stock Offering; Shares Fall - MarketScreener
Xenetic (XBIO) Sets Pricing for New Stock Offering - GuruFocus
Xenetic Biosciences prices of $4.5 million offering of common stock; shares down over 14% - MSN
Xenetic Biosciences prices $4.5 million common stock offering - Investing.com
$4.5M offering: Xenetic Biosciences prices 735,000 shares to fund working capital - Stock Titan
Applying Wyckoff theory to Xenetic Biosciences Inc. stockPortfolio Performance Summary & Expert Verified Movement Alerts - newser.com
Best Pharmaceutical Stocks To Watch Now – October 8th - Defense World
Xenetic Biosciences Inc. recovery potential after sell off2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - newser.com
How moving averages guide Xenetic Biosciences Inc. tradingJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Can Xenetic Biosciences Inc. (3XB0) stock stage a strong rebound this quarterJuly 2025 Final Week & Technical Pattern Recognition Alerts - newser.com
Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real? - ts2.tech
XBIO Shares Skyrocket: Exploring the Surge - StocksToTrade
XBIO Stock Alert: Riding the Market Waves - timothysykes.com
Why Xenetic Biosciences Inc. stock is popular among millennials2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - newser.com
Is Xenetic Biosciences Inc. stock oversold or undervaluedQuarterly Portfolio Review & Verified Technical Signals - newser.com
Is Xenetic Biosciences Inc. (3XB0) stock undervalued by metrics2025 Volatility Report & AI Driven Stock Movement Reports - newser.com
Will Xenetic Biosciences Inc. (3XB0) stock rise with strong economyJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
Using data models to predict Xenetic Biosciences Inc. stock movementQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Is Xenetic Biosciences Inc 3XB0 a good long term investmentMoving Average Strategies & Unlock Free Weekly Portfolio Checkups - earlytimes.in
What drives Xenetic Biosciences Inc stock priceMarket Entry Points & Get Peace of Mind with Portfolio Health Checks - earlytimes.in
What downside risks could hit Xenetic Biosciences Inc. (3XB0) stockJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
Why analysts recommend Xenetic Biosciences Inc. (3XB0) stock2025 Risk Factors & Real-Time Stock Entry Alerts - newser.com
Earnings visualization tools for Xenetic Biosciences Inc.July 2025 Intraday Action & Community Consensus Stock Picks - newser.com
Has Xenetic Biosciences Inc. formed a bullish divergenceJuly 2025 WrapUp & AI Enhanced Trading Alerts - newser.com
Risk adjusted return profile for Xenetic Biosciences Inc. analyzed2025 Trading Recap & Free Long-Term Investment Growth Plans - newser.com
How Xenetic Biosciences Inc. stock trades before earningsEarnings Performance Report & Risk Managed Investment Entry Signals - newser.com
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):